Every S-1 that AETHLON MEDICAL INC (AEMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow AEMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEMD filings page.
Aethlon Medical, Inc. filed Pre-Effective Amendment No. 2 to its Form S-1 registration statement. This amendment is limited in scope and primarily adds an updated consent from the company’s independent registered public accounting firm to the exhibits, with no changes to the prospectus in Part I.
The filing details estimated offering-related expenses of about $450,381.52, including SEC, FINRA, legal, accounting and miscellaneous costs. It also summarizes recent unregistered securities activity, including a December 2025 private placement involving pre-funded and common stock warrants at a $4.03 exercise price, and approximately $200,000 of RSU awards covering 87,260 shares for non-employee directors.
Aethlon Medical, Inc. is conducting a best-efforts offering of up to 4,705,882 shares of common stock, each sold with a warrant, at a combined public offering price of $0.85, for maximum gross proceeds of $4,000,000 and estimated net proceeds of $3,740,000 before expenses. Investors that would exceed a 4.99% ownership cap may buy pre-funded warrants instead of shares, each exercisable for one share at $0.001 with purchase price reduced by $0.001. Each share or pre-funded warrant is paired with a common warrant to buy one share at $0.85, generally exercisable after stockholder approval unless specific Nasdaq pricing conditions are met, and expiring five years after issuance. The placement agent, Maxim Group LLC, will receive a 6.5% cash fee and warrants for 4% of the shares sold, and there is no minimum offering size or escrow, so the company may raise less capital than anticipated while still closing the offering.
Aethlon Medical, Inc. is registering up to 6,000,000 shares of common stock with accompanying warrants in a best‑efforts public offering at $2.00 per share and warrant. The registration also covers pre‑funded warrants, additional warrants, placement agent warrants, and 18,240,000 shares of common stock issuable upon their exercise.
If all securities priced at $2.00 are sold for cash, gross proceeds would be about $12,000,000 and proceeds before expenses about $11,220,000. Aethlon plans to use the funds for research and development, clinical trials, regulatory and manufacturing work on its Hemopurifier device, and general corporate purposes. Shares outstanding could increase from 2,370,560 to 8,370,560 after the offering, meaning substantial dilution for existing holders.
The company highlights a history of operating losses, no current revenue, and substantial doubt about its ability to continue as a going concern without new capital. The offering has no minimum amount and no escrow, so the company may raise significantly less than the maximum, while investors would remain fully committed even if limited proceeds are raised.
Aethlon Medical, Inc. is registering up to 2,031,024 shares of common stock for resale by existing securityholders. These shares are issuable upon exercise of 1,042,820 Common Warrants, 595,897 Pre-Funded Warrants, 368,471 Inducement Warrants and 23,836 Placement Agent Warrants issued in December 2025 private transactions.
The warrants become exercisable only after required Warrant Stockholder Approval under Nasdaq rules; if this approval is not obtained, the Common Warrants will not be exercisable and may have no value. The Common and Inducement Warrants have a $4.03 exercise price, the Placement Agent Warrants a $5.04 exercise price, and the Pre-Funded Warrants a $0.0001 exercise price.
Aethlon will not receive proceeds from the resale of shares, but could receive up to approximately $5.8 million from cash warrant exercises. Shares outstanding were 973,213 as of January 5, 2026 and would be 3,004,237 assuming full exercise of the Registrable Securities. The company is a clinical-stage developer of the Hemopurifier device for cancer, viral infections, and organ transplantation applications.